Genetic Engineering and Biotechnology News – February 8th, 2021 – Products from Novartis and Gilead proved it was possible to win regulatory approval for chimeric antigen receptor T cell (CAR-T) based therapies in 2017. Since then both drugs have illustrated the challenges involved in commercializing such products.